辉瑞为未来增长调整组织架构

2018年7月11日纽约——辉瑞公司今天宣布将公司重组为三块业务：基于科学的创新药品业务（生物类似药和专注于抗感染及无菌注射剂产品的医院业务部也将包括在内）；专注于过专利期品牌药及仿制药、并在辉瑞内部拥有相当自主性的成熟药品业务；以及健康药物业务。这些变化将于2019财年开始生效。

“这一新架构反映了这些业务的自然演进。这是基于我们已上市产品和即将上市的在研产品的持续走强，以及乐瑞卡在美国市场2018年12月（或之后）专利到期后，预计2020年以后由于专利到期所造成的影响将大幅降低。我们预计2020年之后将有更快和更持续的业务收入增长组合。在此过渡期间，我们认为这一新架构将使各块业务更好地定位以达到其增长潜力。”辉瑞公司董事长兼首席执行官晏瑞德（Ian Read）表示。

创新药品业务将包括辉瑞目前所有辉瑞创新医疗业务部门，以及一个新的经营辉瑞全球无菌注射剂和抗感染药品组合的医院药品业务部。这将使我们更加专注和以用户为中心。同时辉瑞还会将生物类似药、肿瘤、炎症及免疫业务并入创新药品业务。这些业务部门在其各自治疗领域都具备很强的医学、商务和患者体验方面的能力，将为这些药品提供一个强大的商业化平台。

人口老龄化带来的对新的创新药物日益增长的需求和生物技术快速发展带来的突破性治疗方案是创新药品业务迅猛增长的基础。辉瑞相信，基于强劲的增长中的上市产品组合、2020年开始预期的新一波新品上市，辉瑞的创新药品业务正蓄势待发。

成熟药品业务将包括辉瑞大部分专利到期固体口服药物品牌，如乐瑞卡、立普妥、络活喜、万艾可等，以及某些仿制药。这块业务将在世界各区域运营。为了让该业务行动迅速和灵活，它将有其自己独有和专职的生产、市场、法规职能，在一些例外情况下还包括支持部门，这将提高其自主性并在辉瑞内部像一个真正独立的部门运作。

在乐瑞卡于2018年12月（或之后）在美国的专利到期所预期造成的影响过后，辉瑞预计成熟药品业务收入有潜力产生可持续的适度增长。新兴市场，尤其是亚洲的城市化和中产阶级的兴起提供了额外的准入机会以及对成熟的品牌药和仿制药的强劲需求。作为在亚洲，尤其是在中国的制药公司，我们相信辉瑞具有在这一重要和快速发展的市场上的优势。

“为全球患者提供关键药物仍然是我们在辉瑞工作的指南。这一新的架构设计能使我们在多元化的市场里更加专注于多元化的患者。”辉瑞首席运营官艾伯乐(Albert Bourla)表示。“此外，这一架构将使成熟药品业务能化其特有的增长机会，同时提供在未来抓住提升其价值的各种机会的灵活性。”

健康药物业务将包括所有辉瑞非处方药产品，将继续相对自主地运营，并将有其专门的生产和法规职能。

健康药物业务基础增长强劲，同时又与其他两块处方药业务有所不同。消费者主义的趋势以及不断增长的对持续健康的专注使消费者寻求易于获得的健康和养生解决方案。拥有一个强大的横跨健康和养生领域的全球品牌组合，公司相信该业务能很好地保持其增长。辉瑞将继续评估该业务的战略选择并预期在2018年内做出决定。

这些组织架构的变化预计不会影响目前的资源分配重点和2018财政年度的财务指南。基于2017年的实际结果，创新药品业务（包括健康药物）预计将占辉瑞总收入的四分之三，成熟药品业务将占大约四分之一。辉瑞将在2019一季度财报发布时提供反映这一新架构的财务报告。

当这些调整生效时，黄玮明（Angela Hwang）和杨宇翰(John Young) 将分别领导辉瑞创新药品业务的不同部分，并向艾伯乐汇报。

杨宇翰，集团总裁，将负责内科药品、肿瘤（包括生物类似药）和罕见病业务部门。此外，他还将负责在所有新兴市场的创新药品业务。

黄玮明，集团总裁，将负责炎症及免疫（包括生物类似药）、疫苗和医院药品业务部。此外，她还将领导辉瑞健康药物业务。

成熟药品业务将由Michael Goettler领导，他将成为辉瑞执行管理团队成员并向艾伯乐汇报。Goettler先生有着23年从业经验，他在2007年随着对惠氏的收购而加入辉瑞。之后担任过一系列职责日益重要的高级管理职务，涉及普药、特药等多个治疗领域。Goettler先生有着丰富的业务管理经验并在多个市场和区域生活和工作过，包括亚太和欧洲。他负责辉瑞罕见病业务并推动公司涉足基因治疗领域。他现任辉瑞炎症及免疫全球总裁。Goettler先生毕业于德国Koblenz企业管理学院并拥有德克萨斯大学MBA学位。

以上架构变化取决于和各地员工组织或工会的协商，以及其他法律要求。

DISCLOSURE NOTICE: The information contained in this release is as of July 11, 2018. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about, among other things, Pfizer, its expected growth profile, its plans to organize the company into a new structure consisting of three businesses and the anticipated performance of those businesses, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the ability to realize the anticipated benefits of the organization of the company into the new structure, including the possibility that the expected benefits from the new structure will not be realized or will not be realized within the expected time period; the risk that the businesses will not be organized into the new structure successfully; the potential for disruption from the organization of the company into the new structure and diversion of management’s attention from other aspects of our business as a result of the organization into the new structure; significant transaction costs; other business effects, including the effects of industry, market, economic, political or regulatory conditions; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; future business combinations or disposals; the uncertainties inherent in research and development, including the ability to meet anticipated trial commencement and completion dates and regulatory submission dates, as well as the possibility of unfavorable clinical trial results, including unfavorable new clinical data and additional analyses of existing clinical data; whether and when any drug applications may be filed in any jurisdictions for any pipeline assets or new indications for marketed products; whether and when regulatory authorities may approve any such applications, which will depend on its assessment of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted and, if approved, whether they will be commercially successful; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of the company’s pipeline assets or marketed products; competitive developments; risks and uncertainties related to our evaluation of strategic alternatives for our Consumer Healthcare business, including, among other things, the ability to realize the anticipated benefits of any strategic alternatives we may pursue for our Consumer Healthcare business, the potential for disruption to our business and diversion of management’s attention from other aspects of our business, the possibility that such strategic alternatives will not be completed on terms that are advantageous to Pfizer, the possibility that we may be unable to realize a higher value for our Consumer Healthcare business through strategic alternatives, and unknown liabilities. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.